Albert Lowe
Stock Analyst at Craig-Hallum
(2.00)
# 2,989
Out of 4,944 analysts
9
Total ratings
55.56%
Success rate
2.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiates: Buy | $50 | $21.11 | +136.85% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.79 | +408.97% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $1.10 | +445.45% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $3.14 | +345.86% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $2.16 | +409.26% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.46 | +225.87% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.03 | +288.35% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.55 | +287.10% | 1 | May 13, 2024 |
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $21.11
Upside: +136.85%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.79
Upside: +408.97%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $1.10
Upside: +445.45%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $3.14
Upside: +345.86%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $2.16
Upside: +409.26%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.46
Upside: +225.87%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.03
Upside: +288.35%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.55
Upside: +287.10%